Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Post archive for ‘Smith On Stocks Blog’

KaloBios: The Fascinating Story of the Takeover of the Company by Martin Shkreli and His Hedge Fund Buddies (KBIO, $18.25, I would not touch this stock)

Investment Thesis and Overview KaloBios (KBIO) announced on November 13 that it was ceasing operations and had engaged a restructuring firm to help liquidate its assets. Management said they were unable to find a strategic partner interested in licensing or acquiring its technology and the Company had only around $5 million of cash. The stock […]

Valeant Pharmaceuticals: What A Sordid Story (VRX, $93.77)

My View on Valeant I have been asked about my feelings on Valeant. I would start out by saying that I have done no detailed research on Valeant and have no existing recommendation nor any investment in the stock. I have no dog in this hunt and my views are based on news reports that […]

Review of SmithOnStocks Recommendations; August 17, 2015

Purpose of Report I am leaving on vacation and will be back on August 27, 2015; you won’t hear from me until then. As the second quarter conference calls and accompanying updates are almost behind us, I thought I would provide a quick summary of where I stand on the15 companies I cover. These are […]

Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno

SmithOnStocks Mailbox  Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno About the Mailbox: My mailbox comments are brief notes on stocks in which I am involved. They can come from recent events or from subscribers’ questions. Comments are meant to address specific issues about these stocks and are not full and balanced reports. […]

Implication of the Juno Celgene Deal for Emerging Immuno-Oncology Biotechnology Stocks in General and Northwest Biotherapeutics in Particular

The Terms of the Juno Celgene Deal Celgene and Juno announced a ten year collaboration for drug development using CAR-T therapy for both cancer and autoimmune diseases. Celgene has the option to commercialize Juno programs outside North America and co-promote certain programs globally. Juno has the option to co-develop and co-promote select Celgene programs. Celgene […]

Illegal Naked Short Selling Appears to Lie at the Heart of an Extensive Stock Manipulation Scheme

Investment Consequences of Naked Shorting Only a motivated enforcement agency with subpoena power and an accompanying powerful enforcement infrastructure can prove that naked shorting is at the heart of an extensive stock manipulation scheme. However, I believe that the observational evidence is overwhelming that naked shorting practices are widely used to manipulate the stock prices […]

Comments on Agenus and Antares

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

Comments on Antares, Kite Pharma and Northwest Biotherapeutics

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

Comments on Agenus, Neuralstem and Celldex

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?

Introduction to This Thought Piece Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually have no or minimal sales and huge operating losses. Many Wall Street analysts arrive at price targets by making long term sales and earnings projections; risk adjusting the estimates through predicting probability of successful […]